インターロイキン1治療薬市場:パイプラインレビュー(2020年上半期)

◆英語タイトル:Interleukin 1 - Pipeline Review, H1 2020
◆商品コード:GDATA20MY0730
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2020年1月14日
◆ページ数:137
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,500 ⇒換算¥367,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD7,000 ⇒換算¥735,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD10,500 ⇒換算¥1,102,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Interleukin 1 – Pipeline Review, H1 2020
Summary

Interleukin 1 (IL1) pipeline Target constitutes close to 24 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes. The latest report Interleukin 1 (IL1) – Pipeline Review, H1 2020, outlays comprehensive information on the Interleukin 1 (IL1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Interleukin 1 (IL1) – Interleukin-1 is a cytokine which plays an important role regulation of immune and inflammatory responses. It helps leukocytes pass through blood vessel walls to sites of infection and causes fever by affecting areas of the brain that control body temperature. There are two forms of interleukin-1, alpha and beta. IL-1 stimulates thymocyte proliferation by inducing IL-2 release, B-cell maturation and proliferation, and fibroblast growth factor activity. The molecules developed by companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 6, 2, 10 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Immunology, Oncology, Cardiovascular, Gastrointestinal, Musculoskeletal Disorders, Dermatology, Metabolic Disorders, Genetic Disorders, Central Nervous System, Ear Nose Throat Disorders, Genito Urinary System And Sex Hormones, Hematological Disorders and Respiratory which include indications Gouty Arthritis (Gout), Non-Small Cell Lung Cancer, Acne Vulgaris, Atopic Dermatitis (Atopic Eczema), Autoimmune Disorders, Behcet Disease, Colorectal Cancer, Epidermolysis Bullosa, Esophageal Cancer, Familial Mediterranean Fever, Inflammation, Metastatic Colorectal Cancer, Metastatic Melanoma, Muckle-Wells Syndrome, Ovarian Cancer, Prostate Cancer, Renal Cell Carcinoma, Rheumatoid Arthritis, Triple-Negative Breast Cancer (TNBC), Type 2 Diabetes, Alcoholic Hepatitis, Allergic Rhinitis, Arterial Thrombosis, Atherosclerosis, Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Brain Cancer, Cancer Anorexia-Cachexia Syndrome, Cancer Pain, Cardiovascular Risk Factors, Cervical Cancer, Cholangitis, Crohn’s Disease (Regional Enteritis), Diffuse Large B-Cell Lymphoma, Endometrial Cancer, Fallopian Tube Cancer, Familial Cold Autoinflammatory Syndrome (Familial Cold Urticaria), Follicular Lymphoma, Gastric Cancer, Glioblastoma Multiforme (GBM), Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hearing Disorders, Hidradenitis Suppurativa, Inflammatory Bowel Disease, Inflammatory Pain, Kidney Cancer (Renal Cell Cancer), Kidney Fibrosis, Limited/Distal Colitis, Liver Fibrosis, Lymphoma, Metastatic Breast Cancer, Metastatic Ovarian Cancer, Metastatic Prostate Cancer, Metastatic Renal Cell Carcinoma, Multiple Myeloma (Kahler Disease), Myocardial Infarction, Neonatal Onset Multisystem Inflammatory Disease, Neuropathic Pain (Neuralgia), Osteoarthritis, Osteosarcoma, Pancreatic Cancer, Pericarditis, Plaque Psoriasis (Psoriasis Vulgaris), Psoriasis, Pyoderma Gangrenosum, Recurrent Glioblastoma Multiforme (GBM), Restenosis, Sarcoidosis, Schnitzler Syndrome, Sickle Cell Disease, Soft Tissue Sarcoma, Squamous Non-Small Cell Lung Cancer, Systemic Juvenile Rheumatoid Arthritis, Systemic Sclerosis (Scleroderma) and Transitional Cell Cancer (Urothelial Cell Cancer).

Furthermore, this report also reviews key players involved in Interleukin 1 (IL1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Interleukin 1 (IL1)
- The report reviews Interleukin 1 (IL1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Interleukin 1 (IL1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Interleukin 1 (IL1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Interleukin 1 (IL1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Interleukin 1 (IL1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Interleukin 1 (IL1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Interleukin 1 (IL1) – Overview
Interleukin 1 (IL1) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Interleukin 1 (IL1) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Interleukin 1 (IL1) – Companies Involved in Therapeutics Development
3SBio Inc
Bioiberica SAU
Devonian Health Group Inc
Johnson & Johnson
Komipharm International Co Ltd
Link Health Group
Mabpharm Ltd
Moderna Therapeutics Inc
Novartis AG
Omnitura Therapeutics Inc
Opsona Therapeutics Ltd
Peptinov SAS
R Pharm
Regeneron Pharmaceuticals Inc
Spherium Biomed SL
Swedish Orphan Biovitrum AB
Therapicon Srl
TWi Biotechnology Inc
XBiotech Inc
Interleukin 1 (IL1) – Drug Profiles
AC-203 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bermekimab – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Interleukin 1 (IL1) – Dormant Products
Interleukin 1 (IL1) – Discontinued Products
Interleukin 1 (IL1) – Product Development Milestones
Featured News & Press Releases
Appendix

List of Tables
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..3), H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Products under Development by Companies, H1 2020 (Contd..5), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by 3SBio Inc, H1 2020
Pipeline by Bioiberica SAU, H1 2020
Pipeline by Devonian Health Group Inc, H1 2020
Pipeline by Johnson & Johnson, H1 2020
Pipeline by Komipharm International Co Ltd, H1 2020
Pipeline by Link Health Group, H1 2020
Pipeline by Mabpharm Ltd, H1 2020
Pipeline by Moderna Therapeutics Inc, H1 2020
Pipeline by Novartis AG, H1 2020
Pipeline by Omnitura Therapeutics Inc, H1 2020
Pipeline by Opsona Therapeutics Ltd, H1 2020
Pipeline by Peptinov SAS, H1 2020
Pipeline by R Pharm, H1 2020
Pipeline by Regeneron Pharmaceuticals Inc, H1 2020
Pipeline by Spherium Biomed SL, H1 2020
Pipeline by Swedish Orphan Biovitrum AB, H1 2020
Pipeline by Therapicon Srl, H1 2020
Pipeline by TWi Biotechnology Inc, H1 2020
Pipeline by XBiotech Inc, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Dormant Products, H1 2020 (Contd..2), H1 2020
Dormant Products, H1 2020 (Contd..3), H1 2020
Dormant Products, H1 2020 (Contd..4), H1 2020
Dormant Products, H1 2020 (Contd..5), H1 2020
Discontinued Products, H1 2020
Discontinued Products, H1 2020 (Contd..1), H1 2020
Discontinued Products, H1 2020 (Contd..2), H1 2020

【掲載企業】

3SBio Inc
Bioiberica SAU
Devonian Health Group Inc
Johnson & Johnson
Komipharm International Co Ltd
Link Health Group
Mabpharm Ltd
Moderna Therapeutics Inc
Novartis AG
Omnitura Therapeutics Inc
Opsona Therapeutics Ltd
Peptinov SAS
R Pharm
Regeneron Pharmaceuticals Inc
Spherium Biomed SL
Swedish Orphan Biovitrum AB
Therapicon Srl
TWi Biotechnology Inc
XBiotech Inc

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[インターロイキン1治療薬市場:パイプラインレビュー(2020年上半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆